A Blood Collection Study to Establish the Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a Potential Biomarker for Predicting Early NonResponse to Therapy in Metastatic Cancer (CADEX-001)

A Blood Collection Study to Establish the Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a Potential Biomarker for Predicting Early NonResponse to Therapy in Metastatic Cancer (CADEX-001)

Trial Category:
Other Solid Tumor
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members